Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens

BACKGROUND: Although CDK4/6 inhibitors are an established treatment for hormone receptor–positive, HER2-negative metastatic breast cancers, their benefit in other malignancies remains limited. METHODS: We investigated factors associated with clinical outcomes from CDK4/6 inhibitor–based therapy amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Shumei, Okamura, Ryosuke, Adashek, Jacob J., Khalid, Noor, Lee, Suzanna, Nguyen, Van, Sicklick, Jason K., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821594/
https://www.ncbi.nlm.nih.gov/pubmed/33427211
http://dx.doi.org/10.1172/jci.insight.142547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821594/
https://www.ncbi.nlm.nih.gov/pubmed/33427211
http://dx.doi.org/10.1172/jci.insight.142547

Ejemplares similares